Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Project Grant - Priority Announcement: Cancer Research

University of Guelph

$100,000.00

Development of boron-based inhibitors of the mitochondrial ClpXP protease to combat AML

EF 2022-23

Résumé
Acute myeloid leukemia (AML) is a type of cancer in which the bone marrow makes abnormal blood cells. The outcome for most AML patients, especially older ones remains poor. Despite advances in the field that include new drug targets, coupled with an increased understanding of cancer biology, the majority of AML patients eventually relapse and die of the disease. Thus, it is critical to investigate novel ways to target AML using strategies that are rooted in a mechanistic understanding of the disease and the infrastructure AML cells use to survive. The mitochondrion is the "powerhouse of the cell" and is a critical player in several biological pathways that lead to cell death. In particular, AML cells have increased reliance on robust mitochondrial function. As such, proteases that help maintain protein quality control in the mitochondria such as ClpXP are promising therapeutic targets in blood cancers. Using a combined biological, structural, and chemical approach we propose to develop therapeutics that target the mitochondrial ClpXP system to fight AML. Our multidisciplinary team comprises a medical doctor specializing in malignant blood disorders, a synthetic organic chemist with expertise in developing novel biologically active molecules, and a structural biologist specializing in protein characterization using spectroscopic tools. Together, we have developed an integrative approach to the design, development, and iterative improvement of new anti-AML agents that operate on the basis of inhibiting ClpXP protease.
Programme
Project Grant - Priority Announcement: Cancer Research
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
472460
Name
Vahidi Siavash
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Cancer Progression & Therapeutics
Projecttitle
Development of boron-based inhibitors of the mitochondrial ClpXP protease to combat AML
Programtype2
Operating Grants
Orgnameinp2
University of Guelph
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant - Priority Announcement: Cancer Research
Keyworddelim
Active Site Inhibitors; Acute Myeloid Leukemia; Blood Cancer; Drug Discovery; In Vivo/In Vitro Biological Assays; Libraries Of Small Molecules; Mitochondrial Matrix Proteases; Nmr Spectroscopy; Protein Degradation; Synthetic Chemistry
Abstract
Acute myeloid leukemia (AML) is a type of cancer in which the bone marrow makes abnormal blood cells. The outcome for most AML patients, especially older ones remains poor. Despite advances in the field that include new drug targets, coupled with an increased understanding of cancer biology, the majority of AML patients eventually relapse and die of the disease. Thus, it is critical to investigate novel ways to target AML using strategies that are rooted in a mechanistic understanding of the disease and the infrastructure AML cells use to survive. The mitochondrion is the "powerhouse of the cell" and is a critical player in several biological pathways that lead to cell death. In particular, AML cells have increased reliance on robust mitochondrial function. As such, proteases that help maintain protein quality control in the mitochondria such as ClpXP are promising therapeutic targets in blood cancers. Using a combined biological, structural, and chemical approach we propose to develop therapeutics that target the mitochondrial ClpXP system to fight AML. Our multidisciplinary team comprises a medical doctor specializing in malignant blood disorders, a synthetic organic chemist with expertise in developing novel biologically active molecules, and a structural biologist specializing in protein characterization using spectroscopic tools. Together, we have developed an integrative approach to the design, development, and iterative improvement of new anti-AML agents that operate on the basis of inhibiting ClpXP protease.
Competitiondate
202209
Approvedterm2
1 yr 0 mth
Pinamesdelim
Vahidi, Siavash; Yudin, Andrei
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~